 The outcome of two other clinical trials evaluating DNAzymes performed in Asia and Europe were reported in 2014 and 2015, the former assessing a Epstein–Barr virus latent membrane protein 1 targeting DNAzyme and the latter a DNAzyme targeting the transcription factor GATA3 which involved 7 trial sites.In both trials, there were no adverse events due to DNAzyme.There was demonstrable efficacy noted in nasopharyngeal cancer patients injected with LMP1 DNAzyme and allergic asthma patients following GATA3 DNAzyme inhalation.